Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Net Cash Flow (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Net Cash Flow readings, the most recent being -$1.9 million for Q4 2017.

  • On a quarterly basis, Net Cash Flow fell 46.65% to -$1.9 million in Q4 2017 year-over-year; TTM through Dec 2017 was $16.2 million, a 912.55% increase, with the full-year FY2025 number at $2.3 million, down 85.83% from a year prior.
  • Net Cash Flow hit -$1.9 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $84.3 million in Q3 2014 to a low of -$35.1 million in Q2 2015.
  • Median Net Cash Flow over the past 5 years was -$1.9 million (2017), compared with a mean of $888470.6.
  • Biggest five-year swings in Net Cash Flow: plummeted 4296.63% in 2015 and later skyrocketed 139.54% in 2017.
  • Eledon Pharmaceuticals' Net Cash Flow stood at $8.6 million in 2013, then crashed by 102.41% to -$208000.0 in 2014, then plummeted by 4296.63% to -$9.1 million in 2015, then skyrocketed by 86.12% to -$1.3 million in 2016, then plummeted by 46.65% to -$1.9 million in 2017.
  • The last three reported values for Net Cash Flow were -$1.9 million (Q4 2017), -$3.4 million (Q3 2017), and $17.6 million (Q2 2017) per Business Quant data.